The latest announcement is out from Aditxt, Inc. ( (ADTX) ).
On February 21, 2025, Aditxt, Inc. hosted a virtual fireside chat where key corporate developments were discussed, including Pearsanta’s planned IPO and advancements in early disease detection. Pearsanta aims to leverage its mitomic platform for early cancer detection, with a focus on diseases like prostate cancer and endometriosis. The IPO is intended to support commercial launches and expand access to these diagnostics globally, starting with a Lab Developed Test (LDT) in the U.S. and distribution in over 40 countries.
More about Aditxt, Inc.
Aditxt, Inc. operates in the biotechnology industry, focusing on innovations that address pressing health challenges. The company identifies, acquires, and develops these innovations into businesses, aiming for global commercialization. One of its subsidiaries, Pearsanta, Inc., is involved in early detection of diseases, particularly cancer, through precision diagnostics and liquid biopsy testing.
YTD Price Performance: -53.33%
Average Trading Volume: 65,350,375
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.22M
Find detailed analytics on ADTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com